Shares of Quantum Biopharma Ltd. (NASDAQ:QNTM - Get Free Report) were up 3.8% during mid-day trading on Friday . The stock traded as high as $23.73 and last traded at $23.37. Approximately 106,783 shares traded hands during trading, a decline of 88% from the average daily volume of 892,441 shares. The stock had previously closed at $22.51.
Analyst Upgrades and Downgrades
Several research firms have recently weighed in on QNTM. Singular Research upgraded shares of Quantum Biopharma to a "moderate buy" rating in a research note on Wednesday, June 18th. Wall Street Zen raised Quantum Biopharma from a "sell" rating to a "hold" rating in a report on Saturday, June 7th.
Get Our Latest Analysis on Quantum Biopharma
Quantum Biopharma Stock Performance
The firm has a market cap of $63.61 million, a P/E ratio of -1.37 and a beta of 0.67. The firm has a 50 day simple moving average of $17.77 and a 200 day simple moving average of $10.30.
Quantum Biopharma (NASDAQ:QNTM - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($1.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by ($1.04). The company had revenue of $2.09 million during the quarter, compared to the consensus estimate of $2.09 million. Sell-side analysts predict that Quantum Biopharma Ltd. will post -3.27 EPS for the current fiscal year.
Institutional Investors Weigh In On Quantum Biopharma
An institutional investor recently raised its position in Quantum Biopharma stock. AdvisorShares Investments LLC lifted its position in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM - Free Report) by 163.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 69,078 shares of the company's stock after buying an additional 42,845 shares during the quarter. AdvisorShares Investments LLC owned approximately 3.60% of Quantum Biopharma worth $254,000 at the end of the most recent quarter. 1.24% of the stock is currently owned by hedge funds and other institutional investors.
Quantum Biopharma Company Profile
(
Get Free Report)
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.
Recommended Stories
Before you consider Quantum Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quantum Biopharma wasn't on the list.
While Quantum Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
